Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRADIENT phase 3 trial of relacorilant for adrenal adenoma- or adrenal hyperplasia-associated hypercortisolism
MOH_2020-08-03_009184Phase 3Not yet recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cushing's syndrome comparing Relacorilant with Placebo (2 arms). Primary endpoints: Blood pressure efficacy assessment and Glucose efficacy assessment. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on MOH_2020-08-03_009184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-03_009184.